investment@revazcapital.com
+91 22 42889999
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 25-07-2018
AUM:
₹ 6,458.59 Cr
Expense Ratio
1.86%
Benchmark
BSE Healthcare TRI
ISIN
INF109KC1GE9
Minimum Investment
5000.0
Minimum Topup
1000.0
Minimum SIP Amount
100
Fund Manager
Dharmesh Kakkad
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option | -0.05 | 26.84 | 16.74 |
| Benchmark | - | - | - |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
39.43
Last change
-0.33 (-0.8369%)
Fund Size (AUM)
₹ 6,458.59 Cr
Performance
20.26% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
To generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. However there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Fund Manager
Dharmesh Kakkad
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 12.05 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 7.9 |
| Dr. Reddys Laboratories Ltd | 7.82 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 7.1 |
| MANKIND PHARMA LIMITED EQ NEW FV RE. 1/- | 6.44 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 5.78 |
| AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 5.19 |
| ALKEM LABORATORIES LIMITED EQ | 3.66 |
| SUVEN PHARMACEUTICALS LIMITED EQ | 3.01 |
| SYNGENE INTERNATIONAL LIMITED EQ | 2.98 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 92.18 |
| Consumer Services | 2.87 |
| Financial Services | 1.71 |
| Chemicals | 1.09 |
